Maxime Dhainaut
YOU?
Author Swipe
View article: 1130 Spatial virtual cell foundation model reveals genotype-specific macrophage programs in the non-small cell lung cancer microenvironment
1130 Spatial virtual cell foundation model reveals genotype-specific macrophage programs in the non-small cell lung cancer microenvironment Open
View article: Plasminogen activator inhibitors orchestrate the immunosuppressive tumor microenvironment in pancreatic cancer
Plasminogen activator inhibitors orchestrate the immunosuppressive tumor microenvironment in pancreatic cancer Open
Summary Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense extracellular matrix (ECM) that sustains an immunosuppressive tumor microenvironment (TME). While this protective niche has been described, the molecular determina…
View article: Supplementary Figure S1 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
Supplementary Figure S1 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma Open
Sex-dependent immune responses in NOTCH1-driven liver tumors
View article: Data from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
Data from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma Open
Hepatocellular carcinoma presents strong sexual dimorphism, being two to three times more frequent in males than in females; however, the role of sex in response to immunotherapies in HCC remains unknown. We demonstrate that NOTCH1, an und…
View article: Supplementary Figure S3 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
Supplementary Figure S3 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma Open
NOTCH1-driven tumors in females lead to impaired CD8+ T cell priming and activation
View article: Supplementary Figure S4 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
Supplementary Figure S4 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma Open
Enhancing DC-T cell axis in females harboring NOTCH1-driven tumors has therapeutic effects
View article: Supplementary Figure S2 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
Supplementary Figure S2 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma Open
Mechanism of immune surveillance in males with NOTCH1 liver tumors
View article: Supplementary Data from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
Supplementary Data from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma Open
RRID list
View article: 1231 Foundation models of cell and tissue biology enabled by custom scaled data generation: insights from 1000 lung tumor samples
1231 Foundation models of cell and tissue biology enabled by custom scaled data generation: insights from 1000 lung tumor samples Open
View article: 861 Multimodal foundation model of human lung tumors identifies tertiary lymphoid structures (TLS) and reveals novel therapeutic targets that promote anti-tumor immune response
861 Multimodal foundation model of human lung tumors identifies tertiary lymphoid structures (TLS) and reveals novel therapeutic targets that promote anti-tumor immune response Open
View article: Supplementary Data from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Supplementary Data from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Supplementary Data
View article: Figure S5 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S5 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S5
View article: Figure S6 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S6 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S6
View article: Figure S1 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S1 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S1
View article: Figure S6 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S6 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S6
View article: Data from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Data from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
PD-1 immune checkpoint inhibitors have produced encouraging results in patients with hepatocellular carcinoma (HCC). However, what determines resistance to anti–PD-1 therapies is unclear. We created a novel genetically engineered mouse mod…
View article: Figure S4 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S4 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S4
View article: Figure S5 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S5 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S5
View article: Figure S4 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S4 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S4
View article: Figure S2 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S2 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S2
View article: Figure S7 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S7 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S7
View article: Figure S7 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S7 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S7
View article: Figure S3 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S3 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S3
View article: Figure S3 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S3 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S3
View article: Figure S2 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S2 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S2
View article: Figure S1 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Figure S1 from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Figure S1
View article: Supplementary Data from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Supplementary Data from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
Supplementary Data
View article: Data from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Data from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma Open
PD-1 immune checkpoint inhibitors have produced encouraging results in patients with hepatocellular carcinoma (HCC). However, what determines resistance to anti–PD-1 therapies is unclear. We created a novel genetically engineered mouse mod…
View article: The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals
The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals Open
Introduction Severe COVID-19 leads to important changes in circulating immune-related proteins. To date it has been difficult to understand their temporal relationship and identify cytokines that are drivers of severe COVID-19 outcomes and…
View article: Model-free Sign Estimation for High-Throughput Screenings
Model-free Sign Estimation for High-Throughput Screenings Open
In high-throughput screenings, it is common to estimate the effects of many treatments using a small number of independent trials of each. Because little is known about the distributional properties of the measurements from these trials, i…